|  |
| --- |
| **WHITE PAPER** |

**1. Project Title**

**2. This proposal represents:**

**[ ]** Continuation of current IIAD-funded research with new deliverable(s)

[ ]  New project

**3. Principal Investigator**

|  |  |
| --- | --- |
| Name: |       |
| Title: |       |
| Primary affiliation:  |       |
| Email:  |       | Telephone:        |  |

 **Co-Principal Investigator**

|  |  |
| --- | --- |
| Name: |       |
| Title: |       |
| Primary affiliation:  |       |
| Email:  |       | Telephone:        |  |

**Investigators, Students and Other Personnel (add additional rows if needed)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** | **Position/Title** | **Affiliation** | **Email** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**4. Estimated Project Budget:**

 **$       Direct**

**$       IDC**

**$       Total (direct and indirect)**

1. **Specific Project Topic Addressed** - *Check all that apply.*

[ ]  **BIOLOGICAL SYSTEMS (BIO) 1.0**

**[ ]** 1.1: Rapid Detection Systems for Diagnosis, Surveillance, Control, Response and Recovery of a Transboundary, Zoonotic or Emerging Disease

[ ]  1.2 Pathogenesis, Interspecies Transmission, and Ecology of Zoonotic and Animal Diseases

[ ]  1.3: High Consequence Pathogen Vaccine Candidates

[ ]  **INFORMATION ANALYSIS SYSTEMS (IAS) 2.0**

[ ]  2.1: Modeling standards

[ ]  2.2: Resiliency (Continuity of Business)

[ ]  2.3: Infectious Disease Epidemiology

[ ]  2.4: Biosurveillance

[ ]  2.5: Novel Approaches to Information Technology

[ ]  **EDUCATION AND OUTREACH (EOS) 3.0**

[ ]  3.1: Curriculum Implementation

[ ]  3.2: First Responder Training

[ ]  **CROSS-CUTTING 4.0**

1. **Summary of Technical Approach and Project Activity:**  *2000 words or less*

Provide a clear and concise summary of the question investigated or problem addressed, methods used, potential outcomes of the project (how its results could be used to enhance transboundary animal, zoonotic and/or emerging disease defense, particularly, capabilities for prevention, detection, response, or recovery in relation to intentional disease outbreak events) and specific end users. In addition, the summary should state how your efforts differ from similar efforts and/or solutions. Specific advances or innovations that indicate significant advancement in the evolution of a topic area identified in this announcement must be clearly stated. Please identify the intended impact(s) and relevance of the project along with the intended end-user. Please state how you will engage with end-user to achieve desired outcomes.

1. **Milestone Chart and “Go/ No Go” Decision Points**

Identify key milestones, associated deliverables, and decision points (“go/no go”). Milestones refer to specific points in the project that demonstrate the project is making appropriate progress toward delivering against the specific research aims. After each milestone should be a “go/no go” decision point (that is, what must occur in order for the project to be successful).

|  |  |  |  |
| --- | --- | --- | --- |
| **Milestone Number** | **Description** | **Decision Point (State the criteria for "go" decision)** | **Deliverable(s)** |
| 1 |  |   |   |
| 2 |   |   |   |
| 3 |   |   |   |
| 4 |   |   |   |
| 5 |   |   |   |
| 6 |   |   |   |
| 7 |   |   |   |
| 8 |   |   |   |
| 9 |   |   |   |
| 10 |   |   |   |

1. **Gantt Chart**

The chart should include: list of milestones and estimated time to complete each milestone, divided by month (example below):

1. **Related Experience/ Qualifications of Principal Investigator and Personnel:** *400 words or less*
2. **Available Resources, Facilities, and Leveraged Funding:** *300 words or less*